Shanghai Kaibao Pharmaceutical (300039) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥190.98 Million ≈ $27.95 Million USD) by net assets (CN¥4.55 Billion ≈ $665.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shanghai Kaibao Pharmaceutical (300039) total market value for the company's overall valuation and market capitalisation.
Shanghai Kaibao Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Shanghai Kaibao Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Kaibao Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their cash flow conversion efficiency. Explore earnings quality score of Shanghai Kaibao Pharmaceutical to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DBV Technologies
NASDAQ:DBVT
|
-0.518x |
|
Sheela Foam Limited
NSE:SFL
|
0.036x |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
0.028x |
|
Worldline SA
PA:WLN
|
0.032x |
|
Karnov Group AB
ST:KAR
|
0.108x |
|
Groupon Inc
NASDAQ:GRPN
|
-0.113x |
|
Viridien
PA:VIRI
|
0.097x |
|
Kunming Chuan Jin Nuo Chemical Co Ltd
SHE:300505
|
0.031x |
Annual Cash Flow Conversion Efficiency for Shanghai Kaibao Pharmaceutical (2006–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Kaibao Pharmaceutical from 2006 to 2025. View current stock price of Shanghai Kaibao Pharmaceutical for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.42 Billion ≈ $646.60 Million |
CN¥230.74 Million ≈ $33.76 Million |
0.052x | -23.19% |
| 2024-12-31 | CN¥4.10 Billion ≈ $600.40 Million |
CN¥278.95 Million ≈ $40.82 Million |
0.068x | -28.35% |
| 2023-12-31 | CN¥4.03 Billion ≈ $590.13 Million |
CN¥382.66 Million ≈ $56.00 Million |
0.095x | -5.19% |
| 2022-12-31 | CN¥3.76 Billion ≈ $550.36 Million |
CN¥376.42 Million ≈ $55.08 Million |
0.100x | +141.71% |
| 2021-12-31 | CN¥3.04 Billion ≈ $445.57 Million |
CN¥126.08 Million ≈ $18.45 Million |
0.041x | -57.41% |
| 2020-12-31 | CN¥2.58 Billion ≈ $377.29 Million |
CN¥250.65 Million ≈ $36.68 Million |
0.097x | -25.23% |
| 2019-12-31 | CN¥2.57 Billion ≈ $376.00 Million |
CN¥334.09 Million ≈ $48.89 Million |
0.130x | +23.16% |
| 2018-12-31 | CN¥2.49 Billion ≈ $363.65 Million |
CN¥262.36 Million ≈ $38.39 Million |
0.106x | +1.62% |
| 2017-12-31 | CN¥2.37 Billion ≈ $346.14 Million |
CN¥245.76 Million ≈ $35.96 Million |
0.104x | -27.40% |
| 2016-12-31 | CN¥2.20 Billion ≈ $321.97 Million |
CN¥314.88 Million ≈ $46.08 Million |
0.143x | -12.25% |
| 2015-12-31 | CN¥2.01 Billion ≈ $293.47 Million |
CN¥327.08 Million ≈ $47.86 Million |
0.163x | +8.85% |
| 2014-12-31 | CN¥1.88 Billion ≈ $275.78 Million |
CN¥282.38 Million ≈ $41.32 Million |
0.150x | -10.95% |
| 2013-12-31 | CN¥1.61 Billion ≈ $235.02 Million |
CN¥270.23 Million ≈ $39.54 Million |
0.168x | -1.89% |
| 2012-12-31 | CN¥1.42 Billion ≈ $207.61 Million |
CN¥243.32 Million ≈ $35.61 Million |
0.171x | +132.79% |
| 2011-12-31 | CN¥1.33 Billion ≈ $195.27 Million |
CN¥98.31 Million ≈ $14.39 Million |
0.074x | +360.54% |
| 2010-12-31 | CN¥1.24 Billion ≈ $181.01 Million |
CN¥19.79 Million ≈ $2.90 Million |
0.016x | -65.23% |
| 2009-12-31 | CN¥1.15 Billion ≈ $167.72 Million |
CN¥52.74 Million ≈ $7.72 Million |
0.046x | -68.76% |
| 2008-12-31 | CN¥126.92 Million ≈ $18.57 Million |
CN¥18.70 Million ≈ $2.74 Million |
0.147x | -51.29% |
| 2007-12-31 | CN¥76.96 Million ≈ $11.26 Million |
CN¥23.27 Million ≈ $3.41 Million |
0.302x | -42.84% |
| 2006-12-31 | CN¥37.24 Million ≈ $5.45 Million |
CN¥19.70 Million ≈ $2.88 Million |
0.529x | -- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more